Should You Buy Off-Brand Semaglutide (Ozempic, Wegovy)? Is Compounded Semaglutide Safe?

The Compounded Semaglutide Debate, Explained by a Doctor

Dr. Jen Caudle is a board-certified family physician who has built a reputation for translating complicated medical topics into practical advice. With 137,000 views, her video on compounded semaglutide clearly hit at a question millions of people are asking: is it safe to buy a cheaper version of Ozempic or Wegovy from a compounding pharmacy? The answer, as you might expect from a careful physician, is not a simple yes or no. It depends on where you get it, who prescribes it, and what standards the pharmacy follows.

The context for this entire conversation is the semaglutide shortage that started in 2022 and persisted through much of 2024. Demand for Ozempic and Wegovy far exceeded Novo Nordisk's manufacturing capacity. Patients with prescriptions could not fill them. Wait lists stretched for months. Into that gap stepped compounding pharmacies, which are legally allowed to produce medications that are on the FDA's drug shortage list. Compounded semaglutide became a $1 billion-plus market seemingly overnight, offering the same active ingredient at a fraction of the branded price.

But "the same active ingredient" is where the nuance starts. Compounded semaglutide is not a generic version of Ozempic. Generics go through the FDA's Abbreviated New Drug Application process, which requires proving bioequivalence to the brand-name drug. Compounded medications do not go through this process. They are prepared on a per-patient basis by compounding pharmacies under a different set of regulations. The quality, purity, potency, and sterility of the final product depend entirely on the pharmacy that makes it.

What Compounding Pharmacies Actually Do

Compounding has a long and legitimate history in pharmacy. Before mass manufacturing, all medications were compounded individually. Today, compounding pharmacies fill an important role by preparing medications in dosage forms or strengths that are not commercially available. A patient who needs a liquid version of a pill, or a specific dose that is not manufactured, or a formulation without an ingredient they are allergic to can have that medication prepared by a compounding pharmacy.

Compounding pharmacies fall into two categories under federal law. Section 503A pharmacies compound medications based on individual patient prescriptions and are primarily regulated by state pharmacy boards. Section 503B pharmacies, called outsourcing facilities, can produce compounded medications in larger batches without patient-specific prescriptions and are registered with and inspected by the FDA. They are held to current Good Manufacturing Practice (cGMP) standards, which are closer to what pharmaceutical manufacturers follow.

Dr. Caudle makes an important distinction here: not all compounding pharmacies are equal. A 503B outsourcing facility that undergoes FDA inspection and follows cGMP standards is a fundamentally different operation from a small 503A pharmacy that may have limited quality control infrastructure. Both can legally produce compounded semaglutide (when it qualifies under shortage rules), but the level of assurance you get about the product is very different.

The risks with lower-quality compounding operations are real and documented. FDA inspections of compounding pharmacies have found contamination issues, incorrect potency, poor sterile technique, and products that failed stability testing. In 2023, the FDA issued multiple warning letters to compounding pharmacies for semaglutide products that contained semaglutide salt forms rather than the base form used in the branded products. Semaglutide sodium and semaglutide acetate have not been studied in clinical trials, and their safety and efficacy profiles may differ from the semaglutide base used in Ozempic and Wegovy. This is not a theoretical concern.

The Salt Form Controversy

This is one of the most technically important issues in the compounded semaglutide debate, and Dr. Caudle walks through it clearly. Novo Nordisk's branded products use semaglutide base, which is the form studied in all the clinical trials that proved the drug's safety and efficacy. Some compounding pharmacies have been using semaglutide sodium or semaglutide acetate, which are different chemical entities. They contain the same peptide, but the salt form can affect stability, absorption, and bioactivity.

The FDA's position is that semaglutide sodium is not the same drug as semaglutide base and therefore may not be compounded under the shortage exception. Novo Nordisk has argued the same point more aggressively, filing lawsuits against compounding pharmacies and lobbying the FDA to restrict compounding even further. Some compounding pharmacies have pushed back, arguing that salt form differences are pharmacologically insignificant and that the FDA's position is driven more by Novo Nordisk's commercial interests than by patient safety.

Dr. Caudle does not take sides on the legal and regulatory fight, but she does note that patients should know what form of semaglutide their compounded product contains and should ask for certificates of analysis (COAs) from the pharmacy. A COA from a third-party lab shows the identity, purity, potency, and sterility test results for the specific batch your product came from. Any reputable compounding pharmacy should provide this without hesitation. If they cannot or will not, that is a meaningful red flag.

How to Evaluate a Compounding Pharmacy

Dr. Caudle provides a practical checklist for patients considering compounded semaglutide. First, check whether the pharmacy is a 503A or 503B facility. 503B outsourcing facilities are listed on the FDA's website and are subject to federal inspection. Second, ask about their testing protocols. Do they do potency testing, sterility testing, and endotoxin testing on every batch? Third, ask for the certificate of analysis for the specific lot number of your product. Fourth, verify that your prescribing physician has actually evaluated you and is monitoring your treatment, more than signing prescriptions through a telehealth mill with no follow-up.

She also raises the point that the cheapest option is not always the safest option. Some online services are offering compounded semaglutide at extremely low prices, which raises questions about how they are cutting costs. If the pharmacy is skipping quality testing, using cheaper salt forms, or not maintaining proper sterile compounding conditions, the lower price reflects lower quality. The potential consequences of contaminated or incorrectly dosed injectable medication are serious enough that saving money should not be the primary decision factor.

That said, Dr. Caudle is sympathetic to the cost problem. Branded Ozempic and Wegovy can cost $1,000 to $1,500 per month without insurance, and many insurance plans do not cover weight loss medications. For patients who cannot afford the branded product and cannot get insurance coverage, a well-sourced compounded semaglutide from a reputable 503B pharmacy is a reasonable and defensible option. The key is doing the homework to verify that the pharmacy meets real quality standards, rather than just choosing the cheapest option you find online.

What Happens When the Shortage Ends

The legal basis for compounding semaglutide rests on the drug being listed on the FDA's official shortage list. If and when Novo Nordisk resolves its supply issues and the FDA removes semaglutide from the shortage list, the legal authority for most compounding pharmacies to produce it goes away. This has already happened for some formulations of semaglutide, and the regulatory space is shifting rapidly.

Dr. Caudle advises patients to have a contingency plan. If you are currently using compounded semaglutide, talk to your physician about what you will do if compounding is no longer available. That conversation might involve switching to branded Ozempic or Wegovy (and navigating insurance coverage), discussing tirzepatide as an alternative (which has its own availability dynamics), or developing a transition plan if you need to stop GLP-1 therapy altogether.

The broader issue is that millions of patients have started on compounded semaglutide and may face disruption if the regulatory environment changes. Physicians, pharmacies, and patients all need to be prepared for that possibility. The worst outcome would be an abrupt loss of access without a plan, because we know from the research that stopping GLP-1 medication without a transition strategy leads to rapid weight regain in the majority of patients.

The Bottom Line on Compounded Semaglutide Safety

Compounded semaglutide from a reputable 503B outsourcing facility that provides certificates of analysis for every batch is a reasonable option for patients who cannot access or afford branded products. The quality standards and testing requirements at these facilities are meaningfully different from unregulated online sources or small pharmacies without robust quality infrastructure. If you are going to use compounded semaglutide, do the work to verify your source, get the COA, confirm the salt form, and make sure you have a prescribing physician who is actually monitoring your health and more than generating prescriptions.

If you cannot verify the source or if the pharmacy cannot provide basic quality documentation, walk away. The money you save on a cheap product is not worth the risk of injecting a contaminated or incorrectly formulated medication into your body every week. This is one of those areas where a few hours of research and a willingness to pay a bit more for quality can make the difference between a safe experience and a genuinely dangerous one. Dr. Caudle's overall message is balanced: the compounding pathway serves a real and important purpose for patients who would otherwise have no access to these medications, but it requires patients to be informed consumers. compounding can be done well and safely, but the patient bears some responsibility for verifying that it actually is.